Pharmacological Research’s Post

Cellular in vitro models are crucial in preclinical research for understanding the pathologies and development of new drugs. However, due to the complex nature of the human body, obtaining accurate cell models can be difficult.   Tebubio, our European distributor, is delivering a webinar on the challenges of in vitro models, exploring the advantages of consolidating biological sample sourcing with a single, reliable partner, and sharing insights into the comprehensive solutions available for cultivating pertinent cellular models.   📅Tuesday 25th June 🕐10:00am BST | 11:00am CEST 💻Register here: https://rb.gy/3j3zel   #CellularResearch #InVitroModels #ResearchEfficiency

Now available – RFdiffusion 2.0 NIM This #NVIDIANIM enables researchers to efficiently design protein therapeutic candidates 1.9x faster due to accelerations in the inference engine, making their preclinical research smarter and less expensive. Get started today. #drugdiscovery

A systematic review of the local field potential adaptations during conditioned place preference task in preclinical studies https://lnkd.in/ey3zFxmM

Pharmaron is using automated high-throughput cell painting and image analysis to transform phenotypic drug discovery. Cell painting with subsequent data analysis with machine learning algorithms enabled us to screen and cluster 390 kinase inhibitors based on their targets and modes of action. We invite you to explore our approach to utilize cell painting by performing fully automated phenotypic drug screening in high-throughput fashion to identify test articles with desired therapeutic effects more efficiently and with greater specificity. Download our poster showing this case study with 390 kinase inhibitors for compound clustering based on their target and mode of action by clicking here: https://buff.ly/3JZMCbB #pharmaron #cellpainting #drugdiscovery #morphologicalprofiling #machinelearning #highcontentscreening #bioinformatics #innovation

In drug discovery, preclinical & clinical development, it's important to get the maximum information from your precious samples. Whether they're fresh, fixed or archived tissues, expensive model organisms, or critical patient biopsies. It's amazing to see the work being done using 10x Genomics single cell and spatial technologies in BioPharma to maximise information gained throughout devlopment, in order minimise late stage failures during clinical trials and increase drug success rates. #drugdevelopment #drugdiscovery #clinicaltrials

𝗙𝗿𝗼𝗺 𝟮𝗗 𝘁𝗼 𝟯𝗗: 𝗘𝘃𝗼𝗹𝘃𝗶𝗻𝗴 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗠𝗼𝗱𝗲𝗹𝘀 𝗳𝗼𝗿 𝗘𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗦𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 https://lnkd.in/dfRtSXjn 👨🔬 "𝘚𝘵𝘢𝘳𝘵𝘪𝘯𝘨 𝘸𝘪𝘵𝘩 𝘴𝘪𝘮𝘱𝘭𝘦 𝟤𝘋 𝘢𝘴𝘴𝘢𝘺𝘴 𝘧𝘰𝘳 𝘳𝘢𝘱𝘪𝘥 𝘤𝘢𝘯𝘥𝘪𝘥𝘢𝘵𝘦 𝘪𝘥𝘦𝘯𝘵𝘪𝘧𝘪𝘤𝘢𝘵𝘪𝘰𝘯, 𝘸𝘦 𝘵𝘩𝘦𝘯 𝘵𝘳𝘢𝘯𝘴𝘪𝘵𝘪𝘰𝘯 𝘵𝘰 𝘮𝘰𝘳𝘦 𝘤𝘰𝘮𝘱𝘭𝘦𝘹 𝟥𝘋 𝘮𝘰𝘥𝘦𝘭𝘴 𝘵𝘰 𝘥𝘦𝘦𝘱𝘦𝘯 𝘣𝘪𝘰𝘭𝘰𝘨𝘪𝘤𝘢𝘭 𝘪𝘯𝘴𝘪𝘨𝘩𝘵𝘴 𝘢𝘯𝘥 𝘦𝘯𝘩𝘢𝘯𝘤𝘦 𝘥𝘳𝘶𝘨 𝘥𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺." ✨ 🎥 Check out this short video by @𝗘𝘂𝗴𝗲𝗻𝗶𝗼 𝗙𝗮𝘃𝗮 from German Center for Neurodegenerative Diseases (DZNE) sharing some great practical insights into recent developments in #neuroscience and early drug discovery. Key Points: 1. 2D Models: Quick and stable for initial screening. 2. 3D Models: Provide advanced biological insights but are more complex. 3. Sequential Approach: Begin with simple models, then introduce complexity. 4. Tissue-like Models: Useful but technically challenging for screening. 5. Oncology: Evidence of 3D model utility despite implementation challenges. Thank you so much for your interest. 🔜 Stay Tuned: #CELLIMATALKS will continue for more on #drugdiscovery, #highcontentimaging, and #bigdata applications in #pharmaceuticalresearch. 🔗 If you'd like to delve deeper into this topic with Eugenio, you can listen to the full interview here: https://lnkd.in/dek8aAqU #lifesciences #CellPainting #Healthcare CELLIMA Scientific Service GmbH

Stop by the BioModels table today to learn more about how we can support your preclinical study needs!

Only a few months ago, Marialessandra Contino and I were funded by the European Commission for the project AID-CARE (Prot. PRIN-PNRR P2022TRR3Y) validating an AI-driven workflow for developing innovative, multi-modal CB2R ligands for treating inflammation-based pathologies such as cancer, neurodegeneration, and pain. 👨🔬 👩🔬 AID-CARE aims to accelerate the drug discovery process by enabling a faster and more advantageous design-make-test-analysis cycle. While working with the AID-CARE team at CNR - ICB STIIMA-CNR Università degli Studi di Bari, we recognized the critical need for a more collaborative approach to drug discovery. Having this aim in mind, we decided to organize the First Cannabinoid Translational Science meeting to create a real occasion for confronting and brainstorming between Molecular Designers and Synthesizers, In Vitro and In Vivo Validation Experts; Prescribing Physicians and Market Experts! 😎 👉 Discover more about our project https://lnkd.in/dWjnhMDv 👉 Discover more about our symposium https://lnkd.in/d7pYCNdT #AIDCARE #CannabinoidTranslationalScience #Cannabinoids #goodscience #networking

From Japan SOT Labcorp session: Cynomolgus macaques are vital for drug research, but did you know their genetics can impact study results? Our latest blog examines how geographic origin shapes subpopulations and its importance in designing studies. Learn more insights on maintaining data integrity and optimizing this key preclinical model. Read the blog: https://lnkd.in/g3P3G4EG #DrugSafety #ClinicalTrials

IPA acquires the Carterra LSA® instrument to enhance antibody discovery and bolster its AI developments. The efficiency gain resulting from the instrument acquisition will not only expedite the Company’s in vitro characterizations for clients and partners, but also rapidly fuels LENSᵃⁱ™ with valuable data sets to optimize models for next gen in silico drug discovery and development utilizing their proprietary HYFTs® to aggregate and integrate biological data. “It represents a strategic move to capture the growing interest in, and huge potential of, AI-driven drug discovery and digital biology. Complementing our well-established high throughput antibody discovery, production, and screening capabilities, Carterra’s LSA moves us closer to making ours the fastest and most cost-effective drug discovery workflow.” Dr Jennifer Bath, IPA CEO stated. See the full release: https://bit.ly/43oM0Fc #DrugDiscovery #TechBio #Ai #ArtificialIntelligence #Antibodies #mAb #Biotechnology Carterra